Oncology - Myeloproliferative Dz News & Articles

1 Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement European Journal of Haematology, May 18, 2012

2 Multiple Myeloma: Myeloablative Therapy with Autologous Stem Cell Support versus Chemotherapy: A Meta-analysis Anticancer Research, May 18, 2012    Evidence Based Medicine    Clinical Article

3 Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome Journal of Clinical Oncology, May 17, 2012    Clinical Article

4 Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells British Journal of Haematology, May 17, 2012

5 Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma American Journal of Hematology, May 16, 2012

6 A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma British Journal of Haematology, May 10, 2012

7 B cell-activating factor: its clinical significance in multiple myeloma patients Annals of Hematology, May 10, 2012

8 Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation Leukemia, May 10, 2012

9 Correlation among DCE-MRI Measurements of bone marrow angiogenesis, microvessel density, and extramedullary disease in patients with multiple myeloma American Journal of Hematology, May 9, 2012

10 The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma European Journal of Haematology, May 8, 2012

11 Dual-energy X-ray absorptiometry and biochemical markers of bone turnover after autologous stem cell transplantation in myeloma European Journal of Haematology, May 7, 2012

12 Comparable outcomes between unrelated and related donors after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high-risk multiple myeloma European Journal of Haematology, May 7, 2012

13 Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study European Journal of Haematology, May 7, 2012    Clinical Article

14 Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy International Journal of Cancer, May 4, 2012    Clinical Article

15 Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma Journal of Clinical Oncology, May 3, 2012    Clinical Article

16 A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes Leukemia Research, May 3, 2012    Clinical Article

17 18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: A systematic review Cancer, May 3, 2012    Evidence Based Medicine

18 Detection of serum tumor markers in multiple myeloma using the CLINPROT system International Journal of Hematology, May 2, 2012    Clinical Article

19 CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients Leukemia, May 1, 2012

20 Durable remission with salvage second autotransplants in patients with multiple myeloma Cancer, April 30, 2012

Stereotactic ablative radiotherapy for stage I NSCLC: Recent advances and controversies Journal of Thoracic Disease, 08/05/2011

1 Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone Journal of Cancer Research & Clinical Oncology, April 20, 2012

2 Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era European Journal of Haematology, April 6, 2012

3 A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF) Cancer, April 24, 2012

4 Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP versus MP: Results from the VISTA trial European Journal of Haematology, April 5, 2012

5 Melphalan 180mg/m² can be safely administered as Conditioning Regimen prior to an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60ml/min/1.73 m² or lower with use of palifermin for Cytoprotection Biology of Blood and Marrow Transplantation, April 2, 2012

6 SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma Annals of Hematology, April 12, 2012    Evidence Based Medicine

7 Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma American Journal of Hematology, March 13, 2012

8 Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents American Journal of Hematology, April 13, 2012

9 Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma International Journal of Hematology, March 26, 2012

10 Hereditary thrombocythemia caused by a thrombopoietin (THPO) gain-of-function mutation associated with multiple myeloma and congenital limb defects Annals of Hematology, April 4, 2012

11 A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid Cancer, April 18, 2012

12 Recent decline in the U.S. death rate from myeloproliferative neoplasms, 1999-2006 Cancer Epidemiology, March 28, 2012

13 Durable remission with salvage second autotransplants in patients with multiple myeloma Cancer, April 30, 2012

14 No association between cigarette smoking and incidence of plasma cell myeloma: A meta-analysis of 17 observational studies American Journal of Hematology, April 9, 2012    Evidence Based Medicine

15 Comparable outcomes between Unrelated and Related donors after Reduced Intensity Conditioning Allogeneic hematopoietic Stem Cell Transplantation in patients with high risk Multiple Myeloma. European Journal of Haematology, March 27, 2012

16 Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma British Journal of Haematology, March 29, 2012

17 Serum concentrations and clinical significance of soluble CD40 ligand in patients with multiple myeloma Medical Oncology, March 12, 2012

18 T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies British Journal of Haematology, March 28, 2012

19 Thalidomide and Dexamethasone Versus Bortezomib and Dexamethasone for Melphalan Refractory Myeloma: A Randomized Study European Journal of Haematology, March 15, 2012

20 Prognostic significance of serum cystatin C in multiple myeloma International Journal of Hematology, March 23, 2012